AAAAAA
Results: 1-25/26
Authors:
Lou, Y
Ge, MT
Freed, JR
Citation: Y. Lou et al., A multifrequency ESR study of the complex dynamics of membranes, J PHYS CH B, 105(45), 2001, pp. 11053-11056
Authors:
Lou, Y
Nagylaki, T
Ni, WM
Citation: Y. Lou et al., On diffusion-induced blowups in a mutualistic model, NONLIN ANAL, 45(3), 2001, pp. 329-342
Authors:
Du, YH
Lou, Y
Citation: Yh. Du et Y. Lou, Qualitative behaviour of positive solutions of a predator-prey model: effects of saturation, P RS EDIN A, 131, 2001, pp. 321-349
Authors:
Sadler, BM
Piliero, PJ
Preston, SL
Lloyd, PP
Lou, Y
Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers, AIDS, 15(8), 2001, pp. 1009-1018
Authors:
Poole, WK
Perritt, R
Shah, KB
Lou, Y
Turner, J
Kvale, P
Hopewell, PC
Glassroth, J
Rosen, M
Reichman, L
Wallace, J
Citation: Wk. Poole et al., A characterisation of patient drop outs in a cohort of HIV positive homosexual/bisexual men and intravenous drug users, J EPIDEM C, 55(1), 2001, pp. 66-67
Authors:
Sadler, BM
Chittick, GE
Polk, RE
Slain, D
Kerkering, TM
Studenberg, SD
Lou, Y
Moore, KHP
Woolley, JL
Stein, DS
Citation: Bm. Sadler et al., Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects, J CLIN PHAR, 41(4), 2001, pp. 386-396
Authors:
Yuen, GJ
Lou, Y
Thompson, NF
Otto, VR
Allsup, TL
Mahony, WB
Hutman, HW
Citation: Gj. Yuen et al., Abacavir/lamivudine/zidovudine as a combined formulation tablet: Bioequivalence compared with each component administered concurrently and the effectof food on absorption, J CLIN PHAR, 41(3), 2001, pp. 277-288
Authors:
Sadler, BM
Gillotin, C
Lou, Y
Stein, DS
Citation: Bm. Sadler et al., In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor, ANTIM AG CH, 45(3), 2001, pp. 852-856
Authors:
Polk, RE
Brophy, DF
Israel, DS
Patron, R
Sadler, BM
Chittick, GE
Symonds, WT
Lou, Y
Kristoff, D
Stein, DS
Citation: Re. Polk et al., Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males, ANTIM AG CH, 45(2), 2001, pp. 502-508
Authors:
Sadler, BM
Gillotin, C
Lou, Y
Eron, JJ
Lang, W
Haubrich, R
Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir, ANTIM AG CH, 45(12), 2001, pp. 3663-3668
Authors:
Sadler, BM
Gillotin, C
Lou, Y
Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing, ANTIM AG CH, 45(1), 2001, pp. 30-37
Authors:
Du, YH
Lou, Y
Citation: Yh. Du et Y. Lou, Proof of a conjecture for the perturbed Gelfand equation from combustion theory, J DIFF EQUA, 173(2), 2001, pp. 213-230
Authors:
Weller, S
Radomski, KM
Lou, Y
Stein, DS
Citation: S. Weller et al., Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects, ANTIM AG CH, 44(8), 2000, pp. 2052-2060
Authors:
McDowell, JA
Lou, Y
Symonds, WS
Stein, DS
Citation: Ja. Mcdowell et al., Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults, ANTIM AG CH, 44(8), 2000, pp. 2061-2067
Authors:
Veronese, L
Rautaureau, J
Sadler, BM
Gillotin, C
Petite, JP
Pillegand, B
Delvaux, M
Masliah, C
Fosse, S
Lou, Y
Stein, DS
Citation: L. Veronese et al., Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virustype 1 protease inhibitor, in subjects with normal or impaired hepatic function, ANTIM AG CH, 44(4), 2000, pp. 821-826
Authors:
Brophy, DF
Israel, DS
Pastor, A
Gillotin, C
Chittick, GE
Symonds, WT
Lou, Y
Sadler, BM
Polk, RE
Citation: Df. Brophy et al., Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers, ANTIM AG CH, 44(4), 2000, pp. 978-984
Authors:
Lemarie, Y
Lou, Y
Citation: Y. Lemarie et Y. Lou, 'Suzhou River', POSITIF, (477), 2000, pp. 95-96
Authors:
Garbarz, F
Valens, G
Lou, Y
Citation: F. Garbarz et al., An interview with Lou Ye, POSITIF, (477), 2000, pp. 97-99
Authors:
Cai, J
Liu, SJ
Lou, Y
Ma, BK
Duan, SQ
Citation: J. Cai et al., Site occupancy of alloying elements and their effects on the D0(3) phase stability in Fe3Al, J MAT SCI T, 15(4), 1999, pp. 339-341
Authors:
Chittick, GE
Gillotin, C
McDowell, JA
Lou, Y
Edwards, KD
Prince, WT
Stein, DS
Citation: Ge. Chittick et al., Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food, PHARMACOTHE, 19(8), 1999, pp. 932-942
Authors:
Polk, RE
Crouch, MA
Israel, DS
Pastor, A
Sadler, BM
Chittick, GE
Symonds, WT
Gouldin, W
Lou, Y
Citation: Re. Polk et al., Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men, PHARMACOTHE, 19(12), 1999, pp. 1378-1384
Authors:
Kumar, PN
Sweet, DE
McDowell, JA
Symonds, W
Lou, Y
Hetherington, S
LaFon, S
Citation: Pn. Kumar et al., Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults, ANTIM AG CH, 43(3), 1999, pp. 603-608
Authors:
Hughes, W
McDowell, JA
Shenep, J
Flynn, P
Kline, MW
Yogev, R
Symonds, W
Lou, Y
Hetherington, S
Citation: W. Hughes et al., Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children, ANTIM AG CH, 43(3), 1999, pp. 609-615
Authors:
Deng, SJ
Yu, B
Lou, Y
Hui, YZ
Citation: Sj. Deng et al., First total synthesis of an exceptionally potent antitumor saponin, OSW-1, J ORG CHEM, 64(1), 1999, pp. 202-208
Authors:
Lou, Y
Ni, WM
Citation: Y. Lou et Wm. Ni, Diffusion vs cross-diffusion: An elliptic approach, J DIFF EQUA, 154(1), 1999, pp. 157-190